Commentary on the endocrine society clinical practice guideline on the "treatment of hypercalcemia of malignancy in adults".
Metabolism: clinical and experimental（2023）
摘要
•Hypercalcemia of malignancy (HCM) occurs in 2–30 % of malignancies•Clinical manifestations depend on severity and/or rapidity of the serum calcium rise•Treatment of the primary disease, including surgery, is instrumental in preventing and treating HCM•The guideline recommends the use of intravenous bisphosphonate (IV BP) or denosumab (Dmab) as initial therapy for HCM•A calcimimetic, an IV BP, or Dmab, are suggested as initial therapy for HCM due to parathyroid carcinomas
更多查看译文
关键词
Antiresorptive therapy,Bisphosphonate,Calcimimetics,Calcitonin,Clinical practice guidelines,Denosumab,Evidence-to-decision framework,GRADE methodology,Hypercalcemia of malignancy,Knowledge gaps,Refractory
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要